The Role of 18F-FDG PET/CT in Staging and Prognostication of Mantle Cell Lymphoma: An Italian Multicentric Study.
18F-FDG PET/CT
Deauville criteria
mantle cell lymphoma
prognosis
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
21 11 2019
21 11 2019
Historique:
received:
06
10
2019
revised:
13
11
2019
accepted:
19
11
2019
entrez:
27
11
2019
pubmed:
27
11
2019
medline:
27
11
2019
Statut:
epublish
Résumé
Mantle cell lymphoma (MCL) is an aggressive lymphoma subtype with poor prognosis in which 18F-FDG-PET/CT role in treatment response evaluation and prediction of outcome is still unclear. The aim of this multicentric study was to investigate the role of 18F-FDG-PET/CT in staging MCL and the prognostic role of Deauville criteria (DC) in terms of progression-free survival (PFS) and overall survival (OS). We retrospectively enrolled 229 patients who underwent baseline and end-of-treatment (eot) 18F-FDG-PET/CT after first-line therapy. EotPET/CT scans were visually interpreted according to DC. The sensitivity, specificity, positive predictive value, negative predictive value and accuracy of PET/CT for evaluation of bone marrow (BM) were 27%, 100%, 100%, 48% and 57%, respectively. The sensitivity, specificity, positive predictive value, negative predictive value and accuracy of PET/CT for evaluation of the gastrointestinal (GI) tract were 60%, 99%, 93%, 90% and 91%, respectively. At a median follow-up of 40 months, relapse occurred in 104 cases and death in 49. EotPET/CT results using DC significantly correlated with PFS, not with OS. Instead, considering OS, only MIPI score was significantly correlated. In conclusion, we demonstrated that MCL is an FDG-avid lymphoma and 18F-FDG-PET/CT is a useful tool for staging purpose, showing good specificity for BM and GI evaluation, but suboptimal sensitivity. EotPET/CT result was the only independent significant prognostic factor that correlated with PFS.
Identifiants
pubmed: 31769415
pii: cancers11121831
doi: 10.3390/cancers11121831
pmc: PMC6966583
pii:
doi:
Types de publication
Journal Article
Langues
eng
Déclaration de conflit d'intérêts
The authors declare they have no conflict of interest.
Références
Clin Lymphoma Myeloma Leuk. 2018 Nov;18(11):731-736
pubmed: 30075973
Eur J Nucl Med Mol Imaging. 2016 Sep;43(10):1837-48
pubmed: 27154522
Hematol Oncol. 2018 Feb;36(1):110-115
pubmed: 29083050
Blood. 2008 Jan 15;111(2):558-65
pubmed: 17962512
J Clin Oncol. 2014 Sep 20;32(27):3059-68
pubmed: 25113753
Clin Nucl Med. 2011 Jun;36(6):452-6
pubmed: 21552023
Ann Oncol. 2014 May;25(5):921-7
pubmed: 24351400
Clin Lymphoma Myeloma Leuk. 2011 Jun;11(3):261-6
pubmed: 21658653
Front Med (Lausanne). 2019 Apr 09;6:70
pubmed: 31024918
Leuk Lymphoma. 2014 Nov;55(11):2484-9
pubmed: 24432895
Ann Hematol. 2015 Dec;94(12):2025-32
pubmed: 26411584
Nucl Med Commun. 2009 Oct;30(10):770-8
pubmed: 19657307
Clin Lymphoma Myeloma Leuk. 2019 Jun;19(6):e266-e272
pubmed: 31000497
Leuk Lymphoma. 2010 Dec;51(12):2171-80
pubmed: 21077737
Ann Nucl Med. 2019 Jul;33(7):449-458
pubmed: 30929200
Blood. 2018 Oct 18;132(16):1647-1656
pubmed: 30154113
Clin Lymphoma Myeloma Leuk. 2019 Aug;19(8):e457-e464
pubmed: 31129112
Eur J Nucl Med Mol Imaging. 2010 Aug;37(9):1633-42
pubmed: 20428863
Blood. 2008 Sep 15;112(6):2583; author reply 2583-4
pubmed: 18779406
Clin Lymphoma Myeloma. 2008 Jun;8(3):159-65
pubmed: 18650179
J Nucl Med. 2017 Jan;58(1):62-68
pubmed: 27469362
Am J Hematol. 2011 Oct;86(10):841-5
pubmed: 21922524
Bone Marrow Transplant. 2013 Sep;48(9):1212-7
pubmed: 23584442
Am J Hematol. 2017 Aug;92(8):806-813
pubmed: 28699667
Eur J Nucl Med Mol Imaging. 2014 Mar;41(3):565-74
pubmed: 24281821
Eur J Nucl Med Mol Imaging. 2008 Jan;35(1):95-9
pubmed: 17786437
Br J Haematol. 2005 Oct;131(1):29-38
pubmed: 16173960
J Clin Oncol. 2014 Sep 20;32(27):3048-58
pubmed: 25113771
Leuk Lymphoma. 2008 Sep;49(9):1693-701
pubmed: 18798104
Cancer. 2012 Jul 15;118(14):3565-70
pubmed: 22180256
Hematol Oncol. 2019 Feb;37(1):39-46
pubmed: 30299563
Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):328-54
pubmed: 25452219
Adv Clin Exp Med. 2015 Mar-Apr;24(2):325-30
pubmed: 25931367
Haematologica. 2020 Jan;105(1):e33-e36
pubmed: 31371411